Organovo Holdings (Seite 157)
eröffnet am 23.10.12 18:24:31 von
neuester Beitrag 11.05.22 09:20:03 von
neuester Beitrag 11.05.22 09:20:03 von
Beiträge: 1.673
ID: 1.177.413
ID: 1.177.413
Aufrufe heute: 3
Gesamt: 314.201
Gesamt: 314.201
Aktive User: 0
ISIN: US68620A2033 · WKN: A2QA6Q · Symbol: ONVO
1,1000
USD
-4,35 %
-0,0500 USD
Letzter Kurs 22:00:00 Nasdaq
Neuigkeiten
Werte aus der Branche Biotechnologie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 3.000,00 | +74.900,00 | |
| 2,4700 | +33,51 | |
| 1,5400 | +25,71 | |
| 12,400 | +23,26 | |
| 0,6889 | +16,78 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 0,8501 | -17,47 | |
| 0,8700 | -20,18 | |
| 5,0550 | -22,71 | |
| 4,6600 | -28,75 | |
| 0,6021 | -35,26 |
Beitrag zu dieser Diskussion schreiben
Feedback
Vielen Dank für die Erklärung.
Ich habe diese Aktie aus Versehen gekauft,weil ich es so interessant fand ,dass man Organe in Zukunft eventuell sogar ausdrucken kann.
Ich habe diese Aktie aus Versehen gekauft,weil ich es so interessant fand ,dass man Organe in Zukunft eventuell sogar ausdrucken kann.
Antwort auf Beitrag Nr.: 45.011.499 von Zerti45 am 09.07.13 19:14:34Organovo ist bisher ein OTC-Wert gewesen, wird jetzt regulär und reguliert an der Nasdaq gehandelt, also keine Schmuddelecke mehr, letztlich eine sehr positive Nachricht.
http://de.wikipedia.org/wiki/Außerbörslicher_Handel
http://de.wikipedia.org/wiki/Außerbörslicher_Handel
Da ich leider kaum englisch lesen kann,kann mir jemand vielleicht ungefähr in kurzen Sätzen den Inhalt der Finanznachrichten erlären?
http://www.finanznachrichten.de/nachrichten-2013-07/27346478…
PR Newswire · Mehr Nachrichten von PR Newswire
Organovo To List Common Stock On New York Stock Exchange MKT
SAN DIEGO, July 9, 2013 /PRNewswire/ --Organovo Holdings, Inc.(OTCQX: ONVO), a biotechnology company focused on delivering breakthrough three-dimensional (3D) bioprinting technology, is pleased to announce that its common shares have been approved to list on the NYSE MKT and will begin trading on the New York Stock Exchange on July 11, 2013. The Company will continue to trade under the symbol "ONVO" but will withdraw its shares from listing on the OTC QX concurrent with listing its shares on the NYSE MKT, the premier US equities market for listing and trading of small growth companies.
"Trading on the New York Stock Exchange is an important milestone for Organovo and will be valuable to our business and shareholders. Our decision to move to the NYSE MKT was based on a firm belief that the exchange offers the best set of conditions for Organovo's success, and thus the best opportunity to add value for our shareholders," saidKeith Murphy, President and CEO of Organovo Holdings, Inc.. "We found NYSE to have made an unparalleled commitment to providing a fertile platform for growth to early stage biotechnology companies, and we look forward to a great future on the exchange."
NYSE MKT is a fully integrated trading venue within the NYSE Euronext community and leverages the NYSE's advanced and innovative market model to offer a premier venue for listing and trading the stocks of small companies. The venue utilizes the trading, connectivity and routing technologies of the NYSE platform and offers superior price discovery, superior liquidity and reduced trading volatility. Listed companies benefit from issuer-selected Designated Market Makers (DMM) that utilize world-class NYSE trading systems to discover and improve prices, dampen volatility, add liquidity and enhance value. In addition, NYSE MKT-listed companies gain access to the brand visibility and are eligible for the issuer services enjoyed by the NYSE Euronext community.
"We welcome Organovo to the NYSE MKT family of listed companies," said Scott Cutler, Executive Vice President, Global Listings at NYSE Euronext. "Organovo will be joining other growth oriented companies in the U.S. taking advantage of the NYSE's advanced and innovative market model to offer a premier value for listing and trading their stocks."
Trading Spotlight
.. nachlegen, zu den Kursen ???!!!??? Gruß B.
With the addition of Ms. Howson to the Board of Directors, and with Mr. Stern stepping down, the Company now has a majority of directors classified as independent and has three independent directors serving on the audit committee, each of which is a requirement for up-listing to either NASDAQ or NYSE.
http://www.finanznachrichten.de/nachrichten-2013-06/27072942…
http://www.finanznachrichten.de/nachrichten-2013-06/27072942…
http://www.sec.gov/Archives/edgar/data/1497253/0001193125132…
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On June 5, 2013, Adam Stern resigned from the Board of Directors (the “Board”) of Organovo Holdings, Inc. (the “Company”). Mr. Stern’s resignation was not the result of any disagreement between Mr. Stern and the Company on any matter relating to the Company’s operations, policies or practices.
On June 5, 2013, the Board appointed Tamar D. Howson as a director to fill the vacancy created by the resignation of Mr. Stern. Ms. Howson was also appointed as a member of each of the Audit, Compensation and Nominating and Governance Committees. The Board determined that Ms. Howson qualifies as an independent director under the listing standards of the Nasdaq Stock Market. There is no arrangement or understanding between Ms. Howson and any other person pursuant to which she was elected as a director. In addition, there are no transactions in which Ms. Howson has an interest in requiring disclosure under Item 404(a) of Regulation S-K.
As a non-employee director, Ms. Howson is eligible to receive compensation in accordance with the Company’s non-employee director compensation policy. Pursuant to this policy, Ms. Howson is entitled to an annual cash retainer of $24,000, which will be prorated for her service during any partial fiscal year. She will also receive a fee of $2,000 for attending each board meeting and $1,000 for attending each committee meeting, and will be reimbursed for her reasonable out-of-pocket expenses incurred in attending such meetings. Upon her election to the Board on June 5th, Ms. Howson received a stock option to acquire 45,500 shares of the Company’s common stock under the 2012 Equity Incentive Plan (the “Initial Option Grant”). The Initial Option Grant vests ratably on a quarterly basis over the next twelve quarterly periods and has an exercise price equal to $3.98 per share, the closing price of the Company’s common stock on June 5, 2013. In addition, pursuant to this policy, Ms. Howson will receive an annual stock option grant following each annual meeting of stockholders in which she continues to serve as a director equal to 0.04% of the Company’s common stock outstanding as of the most recently completed fiscal quarter (rounded to the nearest 500 share) (the “Annual Option Grant”). Each Annual Option Grant will vest on the earlier of one year from the date of grant or the date of the subsequent annual meeting of stockholders.
The Company issued a press release announcing the appointment of Ms. Howson and the resignation of Mr. Stern, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
Item 5.08 Shareholder Director Nominations
On June 5, 2013, the Company’s Board of Directors fixed August 21, 2013 as the date of the Company’s 2013 Annual Meeting of Stockholders (the “2013 Annual Meeting”). Because the 2013 Annual Meeting will be held more than 30 days prior to the one-year anniversary of the date of the Company’s 2012 Annual Meeting of Stockholders, the due dates for the submission of any qualified stockholder proposal or qualified stockholder nominations under the rules of the Securities and Exchange Commission (the “SEC”) and the Company’s bylaws listed in the Company’s 2012 Proxy Statement on Schedule 14A as filed with the SEC on September 17, 2012 are no longer applicable. Any such stockholder proposals or nominations, including any notice on Schedule 14N, intended to be considered for inclusion in the Company’s proxy materials for its 2012 Annual Meeting must be received by the Company at its principal offices by no later than June 20, 2013 and directed to the attention of the Corporate Secretary. Other requirements for inclusion in the Company’s proxy materials are set forth in the rules and regulations promulgated by the SEC and the Company’s bylaws. The Company currently intends to make its proxy materials for its 2013 Annual Meeting available beginning on or about July 12, 2013.
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On June 5, 2013, Adam Stern resigned from the Board of Directors (the “Board”) of Organovo Holdings, Inc. (the “Company”). Mr. Stern’s resignation was not the result of any disagreement between Mr. Stern and the Company on any matter relating to the Company’s operations, policies or practices.
On June 5, 2013, the Board appointed Tamar D. Howson as a director to fill the vacancy created by the resignation of Mr. Stern. Ms. Howson was also appointed as a member of each of the Audit, Compensation and Nominating and Governance Committees. The Board determined that Ms. Howson qualifies as an independent director under the listing standards of the Nasdaq Stock Market. There is no arrangement or understanding between Ms. Howson and any other person pursuant to which she was elected as a director. In addition, there are no transactions in which Ms. Howson has an interest in requiring disclosure under Item 404(a) of Regulation S-K.
As a non-employee director, Ms. Howson is eligible to receive compensation in accordance with the Company’s non-employee director compensation policy. Pursuant to this policy, Ms. Howson is entitled to an annual cash retainer of $24,000, which will be prorated for her service during any partial fiscal year. She will also receive a fee of $2,000 for attending each board meeting and $1,000 for attending each committee meeting, and will be reimbursed for her reasonable out-of-pocket expenses incurred in attending such meetings. Upon her election to the Board on June 5th, Ms. Howson received a stock option to acquire 45,500 shares of the Company’s common stock under the 2012 Equity Incentive Plan (the “Initial Option Grant”). The Initial Option Grant vests ratably on a quarterly basis over the next twelve quarterly periods and has an exercise price equal to $3.98 per share, the closing price of the Company’s common stock on June 5, 2013. In addition, pursuant to this policy, Ms. Howson will receive an annual stock option grant following each annual meeting of stockholders in which she continues to serve as a director equal to 0.04% of the Company’s common stock outstanding as of the most recently completed fiscal quarter (rounded to the nearest 500 share) (the “Annual Option Grant”). Each Annual Option Grant will vest on the earlier of one year from the date of grant or the date of the subsequent annual meeting of stockholders.
The Company issued a press release announcing the appointment of Ms. Howson and the resignation of Mr. Stern, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
Item 5.08 Shareholder Director Nominations
On June 5, 2013, the Company’s Board of Directors fixed August 21, 2013 as the date of the Company’s 2013 Annual Meeting of Stockholders (the “2013 Annual Meeting”). Because the 2013 Annual Meeting will be held more than 30 days prior to the one-year anniversary of the date of the Company’s 2012 Annual Meeting of Stockholders, the due dates for the submission of any qualified stockholder proposal or qualified stockholder nominations under the rules of the Securities and Exchange Commission (the “SEC”) and the Company’s bylaws listed in the Company’s 2012 Proxy Statement on Schedule 14A as filed with the SEC on September 17, 2012 are no longer applicable. Any such stockholder proposals or nominations, including any notice on Schedule 14N, intended to be considered for inclusion in the Company’s proxy materials for its 2012 Annual Meeting must be received by the Company at its principal offices by no later than June 20, 2013 and directed to the attention of the Corporate Secretary. Other requirements for inclusion in the Company’s proxy materials are set forth in the rules and regulations promulgated by the SEC and the Company’s bylaws. The Company currently intends to make its proxy materials for its 2013 Annual Meeting available beginning on or about July 12, 2013.
War heute kurz davor zu schmeißen ...
Hab den Verdacht das da die "Großen" am werkeln sind, Kurs drücken um die Kleinanleger abzuziehen bevor es über die 5 US-Dollar hinaus geht.
Genau das gleiche wie bei Sierra Wireless die standen auch schon mehrfach kurz vor der 12 US-Dollar-Marke und YY Inc. wird in einer Spanne zwischen 24 und 25 US-Dollar +/- 0,5 US-Dollar gehalten und eingesammelt.
Hoffe mal morgen geht es wieder aufwärts, sonst hol ich mir Alimera Sciences ...
Hab den Verdacht das da die "Großen" am werkeln sind, Kurs drücken um die Kleinanleger abzuziehen bevor es über die 5 US-Dollar hinaus geht.
Genau das gleiche wie bei Sierra Wireless die standen auch schon mehrfach kurz vor der 12 US-Dollar-Marke und YY Inc. wird in einer Spanne zwischen 24 und 25 US-Dollar +/- 0,5 US-Dollar gehalten und eingesammelt.
Hoffe mal morgen geht es wieder aufwärts, sonst hol ich mir Alimera Sciences ...
Durchsuchen
